Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2008 2
2009 2
2010 5
2011 3
2012 4
2013 4
2014 3
2015 2
2016 4
2018 7
2019 2
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sung jin yoo (26 results)?
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Gratzke C, et al. Among authors: yoon sj. Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1. Eur Urol. 2018. PMID: 29866467 Free article. Clinical Trial.
Urology as rehabilitation medicine: a literature review.
Kim TB, Kim CH, Kim KT, Yoon SJ, Chung KJ. Kim TB, et al. Among authors: yoon sj. J Exerc Rehabil. 2018 Jun 30;14(3):322-326. doi: 10.12965/jer.1836222.111. eCollection 2018 Jun. J Exerc Rehabil. 2018. PMID: 30018913 Free PMC article. Review.
General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis.
Shim SR, Kim JH, Choi H, Lee WJ, Kim HJ, Bae MY, Hwang SD, Kim KH, Bae JH, Yoon SJ. Shim SR, et al. Among authors: yoon sj. Curr Med Res Opin. 2015 Feb;31(2):353-65. doi: 10.1185/03007995.2014.980887. Epub 2014 Nov 7. Curr Med Res Opin. 2015. PMID: 25350225 Review.
MRI Findings of Renal Myxoma: A Case Report and Literature Review.
Yu SH, Shim YS, Park SH, Choi SJ, Chung DH, Yoon SJ. Yu SH, et al. Among authors: yoon sj. Taehan Yongsang Uihakhoe Chi. 2022 Jan;83(1):162-167. doi: 10.3348/jksr.2019.0174. Epub 2022 Jan 21. Taehan Yongsang Uihakhoe Chi. 2022. PMID: 36237348 Free PMC article.
Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
Shin DG, Kim HW, Yoon SJ, Song SH, Kim YH, Lee YG, Joo KJ, Bae JH, Kang TW, Jeong SJ, Woo SH, Yoo ES, Son H, Koo KC, Kim SW. Shin DG, et al. Among authors: yoon sj. Neurourol Urodyn. 2019 Jan;38(1):295-304. doi: 10.1002/nau.23852. Epub 2018 Oct 12. Neurourol Urodyn. 2019. PMID: 30311691 Clinical Trial.
42 results